biotech / news / / The Manila Times
iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS - from the same manufacturing donor batch, without genetic engineering.
agenT-797 produces distinct immune responses in cancer and ARDS using the same unmodified donor batch.
KEY POINTS
- The therapy drives pro-inflammatory TH1 activation in solid tumor patients but anti-inflammatory TH2 responses in ARDS.
- Clinical use showed complete metastatic cancer remission and improved survival in severe ARDS without genetic engineering.
- The manufacturing platform enables large-scale expansion of iNKT cells, reproducible across disease indications without engineering.
- A randomized Phase 2 trial in acute lung injury (C-1300-02) is underway with initial data expected in 2026.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →